» Articles » PMID: 33415077

Transcriptome Analysis of Ovarian and Uterine Clear Cell Malignancies

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Jan 8
PMID 33415077
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Ovarian and uterine clear cell carcinomas (CCCs) are rare but associated with poor prognosis. This study explored RNA transcription patterns characteristic of these tumors.

Experimental Design: RNA sequencing (RNA-seq) of 11 ovarian CCCs and five uterine CCCs was performed and compared to publicly available data from high grade serous ovarian cancers (HGSOCs). Ingenuity Pathway Analyses were performed. CIBERSORT analyses estimated relative fractions of 22 immune cell types in each RNA-seq sample. Sequencing data was correlated with PD-L1 immunohistochemical expression.

Results: RNA-seq revealed 1,613 downregulated and 1,212 upregulated genes (corrected p < 0.05, |FC |≥10) in ovarian CCC HGSOC. Two subgroups were identified in the ovarian CCC, characterized by ethnicity and expression differences in . There were 3,252 differentially expressed genes between PD-L1+/- ovarian CCCs, revealing immune response, cell death, and DNA repair networks, negatively correlated with PD-L1 expression, whereas cellular proliferation networks positively correlated with expression. In clear cell ovarian clear cell uterine cancer, 1,607 genes were significantly upregulated, and 109 genes were significantly downregulated (corrected p < 0.05, |FC|≥10). Comparative pathway analysis of late and early stage ovarian CCCs revealed unique metabolic and pathways, whereas uterine CCCs had unique Wnt/Ca+, estrogen receptor, and CCR5 signaling. CIBERSORT analysis revealed that activated mast cells and regulatory T cell populations were relatively enriched in uterine CCCs. The PD-L1+ ovarian CCCs had enriched resting NK cells and memory B cell populations, while PD-L1- had enriched CD8 T-cells, monocytes, eosinophils, and activated dendritic cells.

Conclusions: Unique transcriptional expression profiles distinguish clear cell uterine and ovarian cancers from each other and from other more common histologic subtypes. These insights may aid in devising novel therapeutics.

Citing Articles

Infiltration of CD8 cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma.

Fu M, Zhou H, Yang J, Cao D, Yuan Z Sci Rep. 2025; 15(1):4716.

PMID: 39922892 PMC: 11807128. DOI: 10.1038/s41598-025-89270-z.


Effect of knocking out mouse on colonic uptake of the microbiota-generated thiamine pyrophosphate and colon physiology.

Sabui S, Anthonymuthu S, Ramamoorthy K, Skupsky J, Jennings T, Rahmatpanah F Am J Physiol Gastrointest Liver Physiol. 2024; 327(1):G36-G46.

PMID: 38713615 PMC: 11376973. DOI: 10.1152/ajpgi.00065.2024.


Changes in the innate immune response to SARS-CoV-2 with advancing age in humans.

Agrawal S, Tran M, Jennings T, Soliman M, Heo S, Sasson B Immun Ageing. 2024; 21(1):21.

PMID: 38515147 PMC: 10956333. DOI: 10.1186/s12979-024-00426-3.


A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations.

Struzinska I, Hajkova N, Hojny J, Krkavcova E, Michalkova R, Dvorak J Diagn Pathol. 2023; 18(1):72.

PMID: 37303048 PMC: 10259037. DOI: 10.1186/s13000-023-01358-0.


SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production.

Chen L, Shi V, Wang S, Sun L, Freeman R, Yang J J Clin Invest. 2023; 133(15).

PMID: 37279067 PMC: 10378164. DOI: 10.1172/JCI163841.


References
1.
Mitra S, Tiwari K, Podicheti R, Pandhiri T, Rusch D, Bonetto A . Transcriptome Profiling Reveals Matrisome Alteration as a Key Feature of Ovarian Cancer Progression. Cancers (Basel). 2019; 11(10). PMC: 6826756. DOI: 10.3390/cancers11101513. View

2.
Minami K, Hiwatashi K, Ueno S, Sakoda M, Iino S, Okumura H . Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma. Exp Ther Med. 2018; 15(5):4465-4476. PMC: 5920942. DOI: 10.3892/etm.2018.5959. View

3.
Qu Q, Huang Q, Shen Y, Zhu Y, Zhang X . The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer. Tumour Biol. 2015; 37(4):5031-7. DOI: 10.1007/s13277-015-4066-y. View

4.
Alldredge J, Serna-Gallegos T, Gallegos N, VanLeer J, Chang J, Ziogas A . Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival. Gynecol Oncol. 2019; 155(3):483-488. PMC: 7396164. DOI: 10.1016/j.ygyno.2019.10.008. View

5.
Karwacz K, Arce F, Bricogne C, Kochan G, Escors D . PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy. Oncoimmunology. 2012; 1(1):86-88. PMC: 3272426. DOI: 10.4161/onci.1.1.17824. View